CST, 89928SF, DAF/CD55 (E7G2U) Rabbit Monoclonal Antibody (BSA and Azide Free)

Monoclonal Antibody for studying CD55. Validated for Western Blotting,IHC Leica Bond,Immunohistochemistry (Paraffin). Highly specific and rigorously validated in-house, DAF/CD55 (E7G2U) Rabbit Monoclonal Antibody (BSA and Azide Free) (CST #89928) is ready to ship. Product Usage Information This product is the carrier free version of product #31759. All data were generated using the same antibody clone in the standard formulation which contains BSA and glycerol. This formulation is ideal for use with technologies requiring specialized or custom antibody labeling, including fluorophores, metals, lanthanides, and oligonucleotides. It is not recommended for ChIP, ChIP-seq, CUT&RUN or CUT&Tag assays. If you require a carrier free formulation for chromatin profiling, please contact us . Optimal dilutions/concentrations should be determined by the end user. BSA and Azide Free antibodies are quality control tested by size exclusion chromatography (SEC) to determine antibody integrity. Formulation Supplied in 1X PBS (10 mM Na 2 HPO 4 , 3 mM KCl, 2 mM KH 2 PO 4 , and 140 mM NaCl (pH 7.8)). BSA and Azide Free. For standard formulation of this product see product # 31759 Storage Store at -20°C. This product will freeze at -20°C so it is recommended to aliquot into single-use vials to avoid multiple freeze/thaw cycles. A slight precipitate may be present and can be dissolved by gently vortexing. This will not interfere with antibody performance. Specificity / Sensitivity DAF/CD55 (E7G2U) Rabbit Monoclonal Antibody (BSA and Azide Free) recognizes endogenous levels of total DAF/CD55 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Lys110 of human DAF/CD55 protein. Background Decay-accelerating factor (DAF/CD55) is a GPI-linked plasma membrane glycoprotein normally expressed on the surface of vascular endothelial and hematopoietic cells, which are continuously exposed to autologous complement components. In conjunction with other membrane complement regulatory proteins (CD35, CD46, and CD59), DAF/CD55 protects healthy cells from inappropriate complement-mediated lysis (1). DAF/CD55 inhibits activation of the complement cascade by promoting membrane dissociation and inactivation of C3 convertase, which inhibits amplification of the classical and alternative complement cascades (2). Research studies have demonstrated that DAF/CD55 is overexpressed in a variety of solid and liquid tumors, which functions to protect tumor cells from complement-mediated attack (3,4). Given its ability to disable the complement cascade and facilitate immune evasion by tumor cells, DAF/CD55 has received attention as a potential therapeutic target for the treatment of human malignancies. CD55 deficiency is also linked to human disease. The inability to express CD55 on the surface of erythrocytes renders them highly susceptible to complement-mediated lysis, which contributes to the development of paroxymal noctural hemoglobinuria (PNH). PNH is characterized by hemolytic anaemia, pancytopenia, and venous thrombosis (5). Alternate Names CD55; CD55 antigen; CD55 molecule (Cromer blood group); CD55 molecule, decay accelerating factor for complement (Cromer blood group); CHAPLE; Complement decay-accelerating factor; CR; CROM; Cromer blood group antigen; DAF; decay accelerating factor for complement; Rh blood group D antigen; TC Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 78 Source/Isotype: Rabbit IgG